Repligen Corporation - Asset Resilience Ratio
Repligen Corporation (RGEN) has an Asset Resilience Ratio of 28.27% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Repligen Corporation for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how Repligen Corporation's Asset Resilience Ratio has changed over time. See Repligen Corporation (RGEN) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Repligen Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Repligen Corporation (RGEN) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $809.15 Million | 28.27% |
| Total Liquid Assets | $809.15 Million | 28.27% |
Asset Resilience Insights
- Very High Liquidity: Repligen Corporation maintains exceptional liquid asset reserves at 28.27% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Repligen Corporation Industry Peers by Asset Resilience Ratio
Compare Repligen Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Alcon AG
SW:ALC |
Medical Instruments & Supplies | 0.26% |
|
iRay Technology Co Ltd
SHG:688301 |
Medical Instruments & Supplies | 0.68% |
|
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN |
Medical Instruments & Supplies | 29.19% |
|
Jiangsu Nanfang Medical
SHG:603880 |
Medical Instruments & Supplies | 2.27% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 6.36% |
|
I.Ceram SA
PA:ALICR |
Medical Instruments & Supplies | -1.61% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
Annual Asset Resilience Ratio for Repligen Corporation (1999–2024)
The table below shows the annual Asset Resilience Ratio data for Repligen Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.94% | $26.61 Million | $2.83 Billion | -- |
| 2023-12-31 | 0.00% | $0.00 | $2.82 Billion | -- |
| 2022-12-31 | 3.96% | $100.30 Million | $2.53 Billion | -- |
| 2021-12-31 | 0.00% | $0.00 | $2.36 Billion | -- |
| 2017-12-31 | 0.00% | $0.00 | $120.41 Million | -- |
| 2016-12-31 | 6.77% | $19.55 Million | $288.91 Million | -5.33pp |
| 2015-12-31 | 12.09% | $17.68 Million | $146.24 Million | -6.28pp |
| 2013-12-31 | 18.37% | $21.79 Million | $118.64 Million | +7.19pp |
| 2012-12-31 | 11.18% | $10.85 Million | $97.01 Million | -9.06pp |
| 2011-12-31 | 20.24% | $15.40 Million | $76.10 Million | -28.76pp |
| 2010-12-31 | 49.00% | $35.42 Million | $72.29 Million | -7.86pp |
| 2009-12-31 | 56.86% | $40.61 Million | $71.42 Million | -2.55pp |
| 2008-12-31 | 59.41% | $43.82 Million | $73.75 Million | +34.39pp |
| 2007-12-31 | 25.02% | $17.22 Million | $68.84 Million | -26.23pp |
| 2006-12-31 | 51.25% | $14.90 Million | $29.08 Million | +4.23pp |
| 2005-12-31 | 47.02% | $13.45 Million | $28.60 Million | -3.67pp |
| 2004-12-31 | 50.69% | $13.99 Million | $27.61 Million | +16.93pp |
| 2003-12-31 | 33.75% | $10.00 Million | $29.61 Million | +6.07pp |
| 2002-12-31 | 27.68% | $9.18 Million | $33.15 Million | -14.03pp |
| 2001-12-31 | 41.71% | $12.14 Million | $29.11 Million | +17.53pp |
| 2000-12-31 | 24.18% | $7.77 Million | $32.15 Million | -0.09pp |
| 1999-12-31 | 24.27% | $8.81 Million | $36.29 Million | -- |
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-pack… Read more